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initiating therapy could be a cost-effective option compared to a PI based initiating 
therapy in the Greek health care setting.
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TreaTmeNT of chroNIc hePaTITIs c INfecTed (hcv) geNoTyPe 1 PaTIeNTs 
IN The uK
Guerra I.1, Marie L.2, Cure S.1
1OptumInsight, Uxbridge, UK, 2OptumInsight, Nanterre, France
Objectives: Sofosbuvir (SOF) is a uridine analogue polymerase inhibitor. Ledipasvir 
(LDV) is an inhibitor of the hepatitis C virus (HCV) NS5A protein. Efficacy and safety 
have been demonstrated in three phase III clinical trials of LDV/SOF administered 
with or without ribavirin. This analysis evaluated the long-term outcomes of LDV/
SOF in GT1 treatment-naïve (TN) and treatment-experienced protease inhibitor 
failure patients (TE) HCV patients. MethOds: A Markov-model followed 10,000 
patients for a lifetime, with 19% initiating treatment at the compensated cirrhotic 
(CC) stage. In GT1 TN, LDV/SOF for 8 weeks for non-cirrhotic (NC) patients and 12 
weeks for CC patients was compared against SOF with pegylated interferon 2a and 
ribavirin (SOF/PR), SOF with RBV (SOF/RBV) and simeprevir with PR (SMV/PR). In 
GT1 TE, LDV/SOF for 12 weeks was compared with SOF/PR, SMV/PR and no treat-
ment. SVR rates have been reported as 94% for GT1 TN NC and CC patients, 95% and 
86% for GT1 TE NC and CC respectively. SOF/LDV was also well tolerated without 
any reported grade 3/4 adverse events. Results: SOF/LDV was shown to be highly 
effective in preventing advanced liver disease (ALD) and mortality due to HCV. In 
GT1 TN, LDV/SOF prevented more than 800, 200 and 1600 cases of ALD than SMV/
PR, SOF/PR and SOF/RBV. In GT1 TE over 5000 cases of ALD were avoided compared 
with no treatment and over 1000 compared with SMV/PR, and SOF/PR. LDV/SOF was 
also shown to save more than 10 lives compared with SMV/PR, SOF/PR and SOF/
RBV and avoid the death of 50 TE PI failure patients with no available treatment 
option. cOnclusiOns: LDV/SOF was shown to be highly effective in preventing 
progression to ALD and reducing HCV-related mortality with a well-tolerated single 
tablet regimen. This is particular important for protease inhibitor failure patients 
since there are currently no alternative treatment options.
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cosT-effecTIveNess aNd LoNg-Term ouTcomes of sovaLdI (sofosbuvIr) 
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Objectives: Sovaldi (sofosbuvir) is the first nucleotide polymerase inhibitor with 
pan-genotypic activity and a high barrier to resistance. Efficacy of sofosbuvir-
based regimens demonstrated > 90% SVR across genotype (GT) 1-6 in five phase 
III clinical trials of sofosbuvir administered with ribavirin or a combination of 
pegylated interferon alfa and ribavirin (PR). Sofosbuvir is also the first all-oral 
24-week option available for patients unsuitable for interferon (UI). This analy-
sis evaluated the cost-effectiveness and long-term outcomes of sofosbuvir in 
Swedish treatment-naïve genotype GT1/4/5/6 patients and GT2 and 3 patients 
who are treatment-naïve, treatment-experienced, interferon eligible (IE) and 
UI. MethOds: A Markov-model followed 10,000 patients for a lifetime, with 20% 
initiating treatment at the compensated cirrhotic stage. For patients IE SOF/PR 
for 12 weeks was compared to telaprevir, boceprevir and PR, showing the highest 
SVR rates and a favourable safety profile. A societal perspective was adopted by 
considering productivity losses associated with treatment and advanced liver 
disease (ALD). Results: Sofosbuvir regimens, including interferon-free, were 
shown to be cost-saving across all genotypes and against all current treatment 
alternatives in Sweden. In GT1, this novel therapy incurs approximately 42%, 31% 
and 25% lower costs than PR, boceprevir and telaprevir, respectively. Sofosbuvir 
also reduces the burden of HCV. In 10,000 patients, we estimated that on average 
1697, 1417, 607 and 204 cases of compensated cirrhosis, decompensated cirrhosis, 
hepatocellular carcinoma and liver transplant, respectively, and 92 deaths could be 
avoided with sofosbuvir-based regimens compared with telaprevir, boceprevir, PR 
and no treatment. cOnclusiOns: Cost-effectiveness analysis based on a Swedish 
societal perspective (i.e. including productivity losses due to treatment and ALD) 
shows sofosbuvir-based treatments to be cost saving in all genotypes and against 
all current treatment alternatives. In order to optimally allocate scarce societal 
resources, arguably all costs related to HCV treatment need to be included in the 
cost-effectiveness analysis.
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how do decIsIoN maKers IN euroPe vaLue oTher ecoNomIc evaLuaTIoN 
TooLs ThaN cosT-effecTIveNess aNaLysIs for vaccINes?
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Objectives: Other economic evaluation tools than the classical cost-effectiveness 
(CE) analysis exist but the acceptance of these by decision makers is unknown. We 
assessed the value of these new methods among experts and decision makers in 
Europe through a survey. MethOds: Qualitative structured phone-interviews were 
conducted among experts and decision makers in eleven European countries over 
a one year period to evaluate the current and future use of additional economic 
evaluation methods for reimbursement decisions on vaccines. The five additional 
methods were: 1) Return on Investment (RoI); 2) Multi-Criteria Decision Analysis 
(MCDA); 3) Quality of hospital care (QoC); 4) Health care Budget Optimisation (BOM), 
and 5) Macro-Economic Analysis (MEA). Results: One hundred and seventy experts 
were contacted with a 15% participation rate (25 experts participated). In countries 
where CE is formally used like Belgium, the Netherlands, the UK and the Nordic 
countries, the additional methods were considered as relevant by most experts to 
value vaccines: RoI (61%), MCDA (62%), QoC (54%), BOM (54%) and MEA (61%). They 
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cosT-effecTIveNess aNaLysIs of dIffereNT TheraPeuTIc regImeNs IN 
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Sun L., Dong H., Sun J., Wang Y., Shi W., Zhao X., Wu J.
Shenyang Pharmaceutical University, Shenyang, China
Objectives: To evaluate the cost-effectiveness of commonly used antimicrobial reg-
imens in treatment of Community-acquired Pneumonia (CAP) in China. MethOds: 
This was a retrospective study of CAP patients who received different antibiotic 
drugs during their hospitalization in a 1st Class, Grade A hospital in Shenyang, 
Liaoning between January 2011 and June 2012. Cost-effectiveness analysis was 
performed for the common therapeutic regimens based on both clinical practice 
and the main recommended antibacterial treatment of CAP from the perspective 
of society as a whole. For the sensitivity analysis, we used a relative measurement 
method and an absolute measurement method to test the strength of the study’s 
conclusions over a range of assumptions. Results: 203 clinical cases met study 
criteria, and were assigned to the groups of cefuroxime (n= 26), cefmetazole (n= 60), 
cefamandole (n= 32), moxifloxacin hydrochloride (n= 28), erythromycin (n= 28), 
cefmetazole and erythromycin (n= 29). The treatment success rate for the 6 groups 
were 42.31%, 51.67%, 6.25%, 25.0%, 60.71% and 65.52%, respectively, total direct medi-
cal costs were $474.10, $501.21, $1082.43, $1024.46, $404.15 and $555.84, respectively, 
among them, the incremental cost-effectiveness ratio (ICER) of erythromycin group 
and a combination regimen (cefmetazole plus erythromycin) was 31.54, indicating 
that erythromycin and combination of cefmetazole and erythromycin had a positive 
effect on treatment success and a lower total cost. Sensitivity analysis supported 
the dominance of the 2 groups in nearly all scenarios but the variation of treatment 
success rate. cOnclusiOns: Erythromycin monotherapy and a combination of 
cefmetazole and erythromycin were more cost-effective than other regimens in the 
treatment of Community-acquired Pneumonia. Nevertheless, since there was no 
cost-effective threshold in China to compare the cost-effectiveness of the 2 options, 
it remains to be further researched and discussed.
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Objectives: C. difficile is the leading cause of antibiotic associated infectious 
nosocomial diarrhoea. The two main treatments for these patients are fidaxomicin 
and vancomycin. In two phase III randomized controlled trials fidaxomicin was 
found to be non inferior to vancomycin in initial clinical cure of CDI and superior 
in preventing recurrences. The main goal of this economic analysis was to evaluate 
the cost-effectiveness of fidaxomicin versus vancomycin, for the treatment of C. 
difficile infection in Hungary. MethOds: A decision tree model was developed to 
capture the consequences of recurrent infections with both treatment options. 
The model reported two clinical outcomes: clinical cure and recurrent CDI epi-
sodes. Treatment efficacy was estimated through a meta-analysis in a Bayesian 
framework. The model took the third party payer perspective. The incremental 
cost-effectiveness ratio was calculated as the ratio between costs and number of 
avoided recurrent episodes. Uncertainty around model parameters was assessed 
through probabilistic sensitivity analysis. Results: Total average costs for fidax-
omicin and vancomycin therapies were € 3,987 and € 2,505 per patient, respectively. 
The average number of recurrent episodes per patients was lower with fidaxomicin 
therapy (0.13 recurrent episodes/patient) than with vancomycin therapy (0.40 
recurrent episodes/patient). Incremental cost-effectiveness ratio (fidaxomicin 
vs. vancomycin) was € 5,520 per avoided recurrent episode. cOnclusiOns: In 
conclusion, this study found that fidaxomicin has favourable cost-effectiveness 
ratio compared to vancomycin.
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Objectives: Despite the success of current antiretroviral therapies for human 
immunodeficiency virus (HIV) infection, the development of drug resistance repre-
sents a critical issue. Raltegravir is an inhibitor of HIV-1 integrase approved for treat-
ment experienced and naive patients. The present study aimed at conducting an 
economic evaluation of raltegravir vs protease inhibitor (PI) regimen in treatment-
naive patients in Greece. MethOds: A three-stage continuous-time Markov model 
was developed using differential equations, for the cost-effectiveness analysis of 
initiating raltegravir-based therapy as first-line treatment vs initiating protease 
inhibitor (PI) -based therapy as first-line therapy, over a lifetime horizon. Stages of 
the model included progression through successive treatment therapies. Patients 
entered the model with a given CD4 cell count and HIV-1 viral load. After they failed 
or discontinued the current therapy, patients transitioned between eighteen health 
states (defined according to CD4-count and HIV-1 viral load), and progressed to the 
next stage. At any time they could develop acquired immunodeficiency syndrome 
(AIDS), suffer from a coronary heart disease (CHD) or die. Model inputs were col-
lected from the literature and adapted to Greek health care setting using expert 
opinion. Model outcomes included projected number of AIDS cases, number of 
CHD events, number of deaths, life expectancy and incremental cost-effectiveness 
ratios (ICER). The analysis was performed from the perspective of the Greek Social 
Insurance. Results: Patients initiating on the raltegravir-based therapy presented 
longer undiscounted life expectancy compared to those initiating on a PI regimen 
(21.20 vs 18.85 years). The ICER for a raltegravir-initiated treatment strategy vs. 
a boosted PI initiated treatment strategy was 12,757/QALY gained (discounted at 
3%). cOnclusiOns: Results suggest that, over a lifetime horizon, raltegravir based 
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reasonable representation of the selected actual rates. Mortality rates were stratified 
by age. A probabilistic sensitivity analysis (PSA) was performed to account for the 
effect of uncertainty in the model parameters. Results: For the current practice, 
we estimated that annually 75% of CDI cases are new infections; the rest are recur-
rences; 40% of CDI occurs among individuals aged 80+, 41% among 60-79, and 19% 
among those below 60; hospital-based CDI accounted for 69 % of all CDI, while 
community and LTCF based CDI accounted for 26% and 5% of all CDI, respectively. 
The recurrence rates for current antibiotic treatment were estimated at 25.3% and 
35.9% for first and second recurrences, respectively. The recurrence rate for FMT 
was estimated at 10.4%. For the base case, we estimated 79.0 and 64.9 per 100,000 
population cases of CDI for current practice and FMT, respectively. The number of 
deaths is estimated at 5.8 and 4.7 per 100,000 population for current practice and 
FMT, respectively. The results of the cost-effectiveness analysis indicate that in the 
base case, FMT is a dominant strategy. The results of the PSA reveal that for the 
majority of simulations, FMT is dominant (positive incremental QALYs and negative 
incremental cost). cOnclusiOns: The results of the cost-effectiveness analysis 
indicate that FMT appears to be the dominant strategy, with lower costs and better 
outcomes than the existing antibiotic treatments.
PIN72
The ImPorTaNce of seNsITIvITy aNaLysIs IN assessINg cLINIcaL aNd 
ecoNomIc ImPacT of NaTIoNaL ImmuNIzaTIoN Programs: aN examPLe 
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Objectives: To demonstrate the role of sensitivity analysis (SA) in assessing clinical 
and economic impact of national immunization programs. MethOds: We applied 
our recent cost-effectiveness model of pneumococcal vaccination to the local data 
in Slovenia, which is particularly notable for high incidence of community-acquired 
pneumonia (CAP) and acute otitis media (AOM). In the model, we followed the cohort 
of 21,938 Slovenian infants over their lifetime and compared two pneumococcal vac-
cine (PCV) options (PHiD-CV and PCV-13) with each other and with a “no vaccination” 
strategy (NVS) from a payer perspective, both at current and parity prices. The model 
simulated vaccine protection against both pneumococcal diseases (invasive, CAP, 
AOM) and AOM related to non-typeable Heamophilus influenzae (NTHi). We performed 
various sensitivity analyses, including probabilistic Monte Carlo simulations by 
employing parameter values derived from clinical trials and post-marketing surveil-
lance data. Results: SA has shown that PHiD-CV vaccine dominated PCV-13 vaccine 
across the range of parameters, both at current and parity prices, and robustness 
of domination was further confirmed by more than 95% out of 1,000 Monte Carlo 
simulations, where PHiD-CV dominated PCV-13. SA when comparing each vaccine 
with NVS showed that at current prices reduction of CAP, AOM, and myringotomy-
procedure incidence by 50% in children younger than 10 years increased incremental 
cost-effectiveness ratio (ICER) from € 4,237 per quality-adjusted life year (QALY) to 
€ 18,917/QALY for PHiD-CV and from € 16,049/QALY to € 35,040/QALY for PCV-13. At 
current prices, vaccination with PHiD-CV dominated NVS when at least 17.5% of 
parents of sick children would take a paid leave, which – in the Slovenian jurisdiction 
– constitute direct costs; in comparison, corresponding ICER for vaccination with PCV-
13 vs. NVS was € 12,306/QALY. cOnclusiOns: Both base case and SA model findings 
suggest that Slovenian authorities would save resources by implementing national 
immunization program of infants with PHiD-CV as a vaccine of choice.
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vIrus
Novak A.1, Drenth J.P.H.2, de Knegt R.J.3
1Anovak-Services, Apeldoorn, The Netherlands, 2Radboud University, Nijmegen, The Netherlands, 
3Erasmus Medical Center, Rotterdam, The Netherlands
Objectives: This study assesses the PAN-genotypic costs-effectiveness of sofos-
buvir compared with standard of care in the Netherlands. MethOds: Untreated 
hepatitis C virus (HCV) infection results in chronic liver disease. The prevalence in 
The Netherlands is estimated at 0.1-0.4% with 50% of patients having HCV genotype 
1 (GT1), 10% GT2, 30% GT3 and 10% GT4-5-6. Current standard of care (SoC), regardless 
of genotype consists of weekly subcutaneous pegylated interferon-alpha (PegIFN-α ) 
plus daily oral ribavirin. In GT1, the protease inhibitors telaprevir or boceprevir 
are added. Sofosbuvir (SOF), a novel Direct Antiviral Agent (DAA), has consistently 
demonstrated high rates of sustained virological response (SVR) when given with 
ribavirin±PegIFN-α . This cost-effectiveness evaluation is based on a Markov transi-
tion model, that combines efficacy and safety data from published RCTs with SOF 
and SoC in all genotypes with specific attention for subgroups for whom no alterna-
tives are available (no PegIFN-α eligibility). Medical resource use is based on clinical 
guidelines and expert opinion. Costs include treatment costs, monitoring costs, costs 
for treatment of complications and adverse events as well as productivity loss. The 
model has a lifetime horizon and costs are discounted with 4% and outcomes with 
1.5%. Results are presented for an HCV mono-infected population with 20% cirrhotic 
patients. Results: The incremental QALY gain for SOF was 1.23 in PegIFN-α eligible 
patients and 2.68 in those not eligible for PegIFN-α . The incremental costs were € 25,291 
for PegIFN-α eligible patients and € 89,707 for those not eligible for PegIFN-α . The result-
ing PAN-genotypic ICERs were € 20,487 for PegIFN-α eligible patients and € 33,516 for 
those not eligible for PegIFN-α . cOnclusiOns: PAN-genotypic cost-effectiveness is 
demonstrated for sofosbuvir in the treatment of HCV in the Netherlands.
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cosT-effecTIveNess of humaN PaPILLomavIrus vaccINaTIoN 
Programmes ParaLLeL To curreNT rouTINe vaccINaTIoN of  
youNg TeeNage gIrLs
Westra T.A., Postma M.J.
University of Groningen, Groningen, The Netherlands
were however not considered to be able to replace CE except for MEA (14% reported 
that it could replace CE versus 0% for the others). In countries where CE is not 
formally used, the proportion of experts considering them as relevant was lower 
except for the BOM: RoI (46%), MCDA (46%), QoC (18%), BOM (60%) and MEA (33%). 
Most reported barriers for use of the alternative methods were: no political interest, 
unfamiliarity with these methodologies, and lack of robust input data to conduct 
the evaluation. The method selection was most influenced by the appropriate-
ness to the decision-making question, the country, and the vaccine or disease type 
assessed. cOnclusiOns: Creating awareness on additional economic evaluation 
methods may support and facilitate the vaccine reimbursement decision-making 
process in Europe alongside the current CE analysis.
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Delgleize E., Standaert B.
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Objectives: Pneumococcal conjugate vaccines are available in the Netherlands 
against pneumococcal disease in infants and adults. This analysis aimed to identify 
an optimal vaccination strategy between infants and adults when the budget is 
constrained. Extensive sensitivity analysis is performed around herd protection on 
Invasive Pneumococcal Disease (IPD) and Community Acquired Pneumonia (CAP) 
resulting from infant vaccination. MethOds: We developed an optimization model 
linked to a prevalence-based disease management sub-model. This program allows 
finding an optimal solution given an objective function (minimize cases; minimize 
quality-adjusted life-years (QALYs) lost; minimize life-years (LYs) lost) under budget 
constraints. Vaccine efficacy (VE) is based on clinical trial data. The model is run for 
different scenarios seeking for minimum indirect effect on IPD and on CAP in the 
whole population needed to keep infant vaccination as the optimal intervention, 
given a constrained budget. Results: With the current disease burden and vaccine 
coverage rate in the Netherlands and considering an overall VE in adults against 
CAP of 4.5% and against IPD of 37% (estimates based on CAPITA clinical trial results), 
the model shows that vaccinating infants is the optimal strategy that minimizes 
pneumococcal-related events when compared with adult vaccination. If the objec-
tive is to minimize QALYs lost, vaccinating infants remains the optimal selection 
as long as the net indirect effect is ≥ 2% on CAP or ≥ 3% on IPD. When the objective 
is to minimize LYs lost, the minimum indirect effect should be ≥ 3% on CAP or ≥ 7% 
on IPD. Sensitivity analyses show that even if CAP VE in adults is 3 times higher, the 
estimated minimum indirect effect needed is still below the one obtained with the 
first pneumococcal conjugate vaccine. cOnclusiOns: The optimal strategy within 
a constrained budget is to maintain infant vaccination instead of initiating elderly 
vaccination, given the reported evidence of indirect protection.
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Objectives: A live-attenuated vaccine aimed at preventing herpes zoster (HZ) and 
post-herpetic neuralgia (PHN) is available in Europe for immunocompetent adults 
aged ≥ 50 years. The study objective is to assess the incremental cost-effectiveness 
ratio (ICER) of a vaccination program for this population in Spain when compared 
against the current strategy of no-vaccination. MethOds: A state-transition 
Markov model has been developed to simulate the natural history of HZ and PHN 
and the lifetime effects of vaccination. Several health states are defined including 
good health, HZ, PHN and death. HZ and PHN health states are divided to reflect 
pain severity. The Markov cycle was 1 month and lifetime horizon. The HZ vaccine 
lifetime duration (waning rate of 8.3%) and a PHN vaccine duration of 10 years. PHN 
proportion was obtained from Cebrián-Cuenca (2011) and adjusted to reflect the 
incidence of PHN among HZ patients with pain. The vaccine coverage rate estimated 
was 30%, considering discount rates of 3% for costs and utilities. The strength of the 
results was confirmed with a probabilistic analysis based on Monte Carlo simula-
tion. Results: A vaccination strategy compared to a no-vaccination resulted in 
12.659€ /QALY and 11.926€ /QALY under third-party payer perspective and societal 
perspective respectively for the population aged ≥ 50 years. ICERs were within the 
commonly accepted thresholds of 30.000£/QALY (36.000€ /QALY) gained in the UK. 
Sensitivity analyses showed that the model was most sensitive to discount rates 
and duration of vaccine protection. The lowest ICER was observed for the 70-74 years 
age group (6.657€ /QALY under third-party payer perspective). cOnclusiOns: In 
Spain, a shingles vaccination strategy in older population would be a cost-effective 
alternative in comparison with no vaccination, due to an ICER of 12.659€ /QALY from 
the third-party payer perspective.
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Objectives: To estimate the cost-effectiveness of Fecal Microbiota Transplant 
(FMT) for Clostridium difficile infection (CDI) as compared to the current practice 
comprising of antibiotic treatments. MethOds: We developed a decision analytic 
model to compare strategies for the management of CDI, by age, gender, and three 
sources of infection: hospitals, communities, and long-term care facilities (LTCF). We 
performed validation analyses to demonstrate that the predicted CDI rates were a 
